Plus Therapeutics, Inc.

Informe acción NasdaqCM:PSTV

Capitalización de mercado: US$8.0m

Plus Therapeutics Crecimiento futuro

Future controles de criterios 2/6

Plus Therapeutics is forecast to grow earnings and revenue by 7% and 63.9% per annum respectively while EPS is expected to grow by 26.6% per annum.

Información clave

7.0%

Tasa de crecimiento de los beneficios

26.6%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs27.1%
Tasa de crecimiento de los ingresos63.9%
Rentabilidad financiera futuran/a
Cobertura de analistas

Low

Última actualización02 Oct 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Plus Therapeutics jumps 18% as JonesTrading adds another Buy rating

Oct 07

Plus Therapeutics finalizes $17.6M grant from Texas, to get initial funds by October end

Sep 22

Plus Therapeutics GAAP EPS of -$0.24 misses by $0.02

Jul 21

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:PSTV - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
FechaIngresosBeneficiosFlujo de caja libreFlujo de caja operativoNúm. de analistas medio
12/31/2026N/A-43-61-603
12/31/20254-26-42-284
12/31/20245-14-14-124
6/30/20246-13-11-10N/A
3/31/20246-12-12-12N/A
12/31/20235-13-13-13N/A
9/30/20234-15-13-13N/A
6/30/20233-17-15-15N/A
3/31/20231-21-15-15N/A
12/31/20220-20-14-13N/A
9/30/20220-19-14-13N/A
6/30/2022N/A-17-12-11N/A
3/31/2022N/A-15-12-11N/A
12/31/2021N/A-13-10-10N/A
9/30/2021N/A-13-11-11N/A
6/30/2021N/A-11-11-11N/A
3/31/20210-10-11-10N/A
12/31/20200-8-9-8N/A
9/30/20201-4-5-4N/A
6/30/20206-2-5-4N/A
3/31/20206-2-4-4N/A
12/31/20197-4-6-6N/A
9/30/20197-7-9-9N/A
6/30/20192-11-10-10N/A
3/31/20192-9-11-11N/A
12/31/20183-11-12-12N/A
9/30/20184-18-14-14N/A
6/30/20185-19-15-15N/A
3/31/20186-24N/A-17N/A
12/31/20176-27N/A-18N/A
9/30/20178-23N/A-18N/A
6/30/20179-24N/A-19N/A
3/31/201710-24N/A-19N/A
12/31/201611-22N/A-20N/A
9/30/201612-20N/A-20N/A
6/30/201612-13N/A-21N/A
3/31/201612-2N/A-20N/A
12/31/201512-19N/A-20N/A
9/30/201512-24N/A-21N/A
6/30/201511-34N/A-22N/A
3/31/20159-51N/A-26N/A
12/31/20148-39N/A-30N/A
9/30/20147-42N/A-35N/A
6/30/20149-38N/A-36N/A
3/31/201410-29N/A-34N/A
12/31/201312-26N/A-35N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: PSTV is forecast to remain unprofitable over the next 3 years.

Beneficios vs. Mercado: PSTV is forecast to remain unprofitable over the next 3 years.

Beneficios de alto crecimiento: PSTV is forecast to remain unprofitable over the next 3 years.

Ingresos vs. Mercado: PSTV's revenue (63.9% per year) is forecast to grow faster than the US market (8.9% per year).

Ingresos de alto crecimiento: PSTV's revenue (63.9% per year) is forecast to grow faster than 20% per year.


Previsiones de crecimiento de los beneficios por acción


Rentabilidad financiera futura

ROE futura: Insufficient data to determine if PSTV's Return on Equity is forecast to be high in 3 years time


Descubre empresas en crecimiento